Pharmaceuticals Lipids Market

Market Overview

The global pharmaceuticals lipids market size was valued at USD 4.45 billion in 2021. It is projected to reach USD 7.07 billion by 2030, growing at a CAGR of 5.2% during the forecast period (2022–2030).

In the pharmaceutical business, lipids and polymers are regarded as two of the essential excipients that can be used in drug formation. They are utilized in various capacities, including stabilizers, solubilizers, permeation enhancers, transfection agents, and others. Using a broad range of natural, synthetic, semi-synthetic, or entirely artificial lipids and polymers in developing various dosage forms is anticipated to drive market growth over the ensuing period.

The increasing demand for medications worldwide is driving the manufacture of liposomal pharmaceuticals to treat cancer and excipients. The American Association of Pharmaceutical Scientists (AAPS) reports that approximately 90% of pharmaceuticals are still in the research and development phase, and 40% of drugs currently on the market have poor solubility in water. It has increased demand for lipid-based formulations in pharmaceuticals, diagnostics, vaccines, and nutraceuticals.

Market Dynamics

Market Drivers

• Increase in Neurological, Cardiovascular, and Cancer Patients to Support Market Growth

There has been a significant uptick in most neurological conditions worldwide, including Alzheimer's, dementia, epilepsy, stroke, multiple sclerosis, and migraine, Parkinson's disease, and brain tumors. Because of the rising prevalence of these disorders, it is of the utmost importance to research, produce, and make available effective medicines to treat these conditions. As a result of the fact that lipids' active pharmaceutical substances provide crucial medicinal effects to these patients and help in the healing process, their use and incorporation in medications have expanded significantly, which has benefited the market. Furthermore, according to statistics from the World Health Organization (WHO), cardiovascular illnesses are the leading cause of death globally, accounting for almost 17 million fatalities annually. The prevalence of cardiovascular diseases has increased dramatically over the past few decades due to people's sedentary lifestyles and poor eating habits.s

Market Restraints

• Improvements in the Product Quality to Hinder Market Growth

Stringent quality regulations by various governments worldwide have significantly impacted the market's growth because manufacturers of the active pharmaceutical components found in lipids cannot improve the process design. These quality standards have a detrimental effect on producers' profitability and increase the time and money spent on product development. GMP, which stands for "Good Manufacturing Practices," ICH, which stands for "International Conference on Harmonization," and cGMP are a few examples of these standards (current GMP). In addition, patent expirations have been a significant obstacle to revenue development. These issues make it more challenging to maintain a steady supply of lipids' active medicinal ingredients on a more significant and widespread scale worldwide.

Market Opportunities

• Rising Demand for Effective and Fast-Acting Medications to Spur Market Opportunities

Expanding the medical community's understanding of the therapeutic and curative potential of lipid-based active pharmaceutical ingredients has a beneficial impact on the use of these compounds in pharmaceutical products worldwide. Multiple organizations, firms, and educational institutions are currently engaged in significant research and development operations to enhance the effects of these substances. This has resulted in the general acceptance of lipids' active pharmaceutical ingredients in various medicinal treatments and has presented the lucrative potential for expanding the market.

In addition, considerable potential for expansion has been established due to the rising demand among healthcare businesses for both practical and quick-acting pharmaceuticals in treating various diseases and conditions, including cancer, cardiovascular disorders, and others. In addition, manufacturers can now generate vast quantities of lipids' active pharmaceutical ingredients due to the continual development of more sophisticated and superior facilities for the synthesis of drugs. As a result of an increase in their manufacturing, their application in various contexts will expand.

Regional Analysis

The global pharmaceuticals lipids market is segmented into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.

It is anticipated that the market in North America will represent a sizable income share in the global market for medication lipids due to the enormous amount the government spends on the research and development of new drugs. Factors such as the availability of cutting-edge infrastructure for research and development activities and many players operating in the nation will help the market flourish. In addition, leading market players' method toward business expansion through acquisitions is relied upon to assist in developing the market. The United States will continue to see significant demand during the forecast period.

The Asia-Pacific area is developing quickly, and a significant portion of its growth is invested in research and development operations to create more effective medicines. In addition, an upsurge in the number of people with cancer, cardiovascular diseases, and neurological disorders—particularly in China, India, and Japan—has resulted in a tremendous increase in lipids as active medicinal ingredients in the manufacture of medicines.

Segmental Analysis

The pharmaceuticals lipids market is broken down into distinct submarkets based on product, source, form, application, and route of administration.

On the Basis of Product

Based on product, the market is segmented into triglycerides, phospholipids, sphingolipids, cholesterol, and fatty acids.

The triglycerides market category is the most dominant and is expected to grow at a CAGR of 5.1% during the forecast period. Many different types of personal care products use these lipids in various ways. For example, caprylic triglyceride or capric triglyceride production involves the combination of glycerine and the fatty acids found in natural oils such as coconut oil. Binding other components, including essential oils, are standard in cosmetics and soaps.

On the Basis of Source

Based on the source, the market is segmented into synthetic, semi-synthetic, and natural components.

Demand for products derived from semi-synthetic sources is anticipated to grow at a CAGR of 5.8% during the forecast period. The chemical structure of semi-synthetic pharmaceuticals is modified, but the nucleus of the medication derived from a natural source is maintained in its original form. Heroin is derived from morphine; bromoscopolamine, derived from scopolamine; homatropine, derived from atropine; ampicillin, derived from penicillin; and so on are all examples of semi-synthetic medications. Plants are the most common source of natural medicines due to their chemical and structural variety and their wide variety of constituent parts. Aspirin, oral anti-diabetics, antihistamines, amphetamine, chloroquine, chlorpromazine, and general and local anesthetics are all medications prepared synthetically.

On the Basis of Form

Based on form, the market is segmented into liquid, semi-solid, and solid.

It is anticipated that the semi-solid segment will dominate the market. Cosmetic formulations with nano-drug delivery systems are referred to as nano-cosmeceuticals. These formulations are intended to convey active compounds to the appropriate skin tissues. Many different kinds of semi-solid nanostructured lipid carriers are utilized for medication delivery.

On the Basis of Application

Based on application, the market is segmented into Liposomes, solid lipid nanoparticles; nanostructured lipid carriers; conventional lipid-based drug delivery systems; self-emulsifying drug delivery systems; self-micro emulsifying drug delivery systems; conventional lipid-based drug delivery systems.

The conventional lipid-based drug delivery systems (LBDDS) segment will dominate the market. One of the developing technologies aiming to solve difficulties such as the solubility and bioavailability of poorly water-soluble pharmaceuticals is LBDDS. The requirements are determined by the disease indication, route of administration, cost considerations, product stability, toxicity, and efficacy. Lipid-based formulations can be adapted to fulfill all of these needs.

On the Basis of Routes of Administration

Based on routes of administration, the market is segmented into oral, tablet, solution, parenteral, intravenous, intramuscular (vaccines), and topical.

The oral lipids segment dominates the market during the forecast period. Oral formulations based on lipids are gaining popularity because they increase the solubility of poorly water-soluble and lipophilic drugs. It also facilitates absorption of these drugs through the gastrointestinal tract and reduces or eliminates the effect of food on the absorption of these drugs.

Recent Developments

• June 2022- BASF offers a range of chemical intermediates with a product carbon footprint significantly below the global market average.
• February 2022- Xampla and Croda / Incotec to work on biodegradable seed coatings.
• April 2022- Cordenpharma and wacker to produce mRNA vaccines for Germany.
• January 2022- Phospholipid-Based Delivery Systems – Advanced Pulmonary Applications Using Phospholipids.